|Bid||5.40 x N/A|
|Ask||6.00 x N/A|
|Day's Range||5.36 - 5.36|
|52 Week Range||1.90 - 8.45|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.77|
VANCOUVER and HOUSTON , March 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company also provided a business update as the COVID-19 situation rapidly evolves.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
HOUSTON and VANCOUVER, Feb. 27, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on February 27, 2020 in Vancouver, British Columbia, Canada (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") set the number of directors at nine and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach, and Ari Brettman to serve in office until the next annual meeting or until their successors are duly elected or appointed.
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
HOUSTON and VANCOUVER, Oct. 30, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares"). The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date.